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Abstract
Background: We have previously shown that a combination of glucosyl hesperidin (G-hesperidin) plus
caffeine reduces accumulation of body fat, whereas G-hesperidin or caffeine alone shows little effect on
high-fat diet-induced obesity in mice. The aim of this study is to evaluate the anti-obesity effect of
G-hesperidin plus caffeine on body fat and serum TG in healthy subjects with moderately high body
mass index (BMI) and serum TG. Since we considered that there are individual differences in caffeine
sensitivity, we conducted dose-finding study of caffeine combined with G-hesperidin.
Methods: Seventy-five healthy subjects with moderately high BMI (24–30 kg/m2) and serum TG (100–250 mg/dl)
were divided and assigned to 12-week intervention with daily intakes of 500 mg of G-hesperidin with or without 25,
50, or 75 mg of caffeine, or placebo in a randomized double-blind placebo-controlled design .
Results: After intervention, decreases in abdominal fat area (AFA), especially subcutaneous fat area (SFA),
were significantly greater in the G-hesperidin with 50-mg caffeine group (AFA:-8.4 ± 21.9 v.s. 16.3 ± 34.1 cm2;
p < 0.05, SFA: -9.3 ± 17.1 v.s. 11.2 ± 18.3 cm2; p < 0.01) and in the G-hesperidin with 75-mg caffeine group
(AFA:-17.0 ± 31.4 v.s. 16.3 ± 34.1 cm2; p < 0.01, SFA: -12.4 ± 18.7 v.s. 11.2 ± 18.3 cm2; p < 0.01) than in the
placebo group. Fat-decreasing effects of G-hesperidin were enhanced dose-dependently by caffeine
addition. BMI decreases were significantly greater in the G-hesperidin with 75-mg caffeine group than in
the placebo group (-0.56 ± 0.74 v.s. -0.02 ± 0.58 kg/m2; p < 0.05). G-hesperidin with/without caffeine had
no effect on serum TG (p > 0.05 v.s. placebo).
Conclusions: These data suggested that a combination of 500-mg G-hesperidin with 50- or 75-mg caffeine
may be useful for the prevention or treatment of obesity.
Trial registration: UMIN Clinical Trials Registry 000019241.
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Background
Prevalence of obesity continues to increase worldwide,
mainly as a result of changing lifestyles. It is known that
visceral fat-type obesity induces type-2 diabetes mellitus,
hyperlipidaemia, hypertension and increases the risk of
cardiovascular disease [1–3]. Subcutaneous fat-type
obesity is associated with excessive weight gain, and is
thought to be the main risk factor for osteoarthritis of
the knee [4–7], sleep apnoea [8], and menstrual abnor-
malities [9–11]. Consequently, research on the preven-
tion and treatment of obesity has been expanded.
Glucosyl hesperidin (G-hesperidin) is synthesized by
enzymatic means from hesperidin purified from oranges
(Citrus aurantium) and dextrin. Its solubility in water is
over 10,000-fold greater than that of hesperidin [12]. G-
hesperidin has been reported to reduce serum levels of
triglyceride (TG) in animals [13–15] and subjects with
hypertriglyceridemia [16, 17]. The mechanism of the TG-
lowering effect of G-hesperidin is thought to be down-
regulation of the synthesis/secretion of very-low-density
lipoprotein in hepatocytes [18], inhibition of lipogenesis,
and induction of beta oxidation of fatty acids in high-fat
diet-fed rats [15]. Studies have shown that daily intake of
G-hesperidin (500 mg) in subjects with a moderately high
BMI for 12 weeks decreases abdominal fat significantly
during the period, but these decreases do not differ
significantly from those of subjects taking a placebo
[19]. Therefore, the anti-obesity effect of G-hesperidin
is incompletely understood.
Caffeine is one of the most widely consumed dietary
components (e.g., tea, coffee) with pharmacological effects
and psychostimulant activity. Caffeine has been reported
to induce lipolysis of adipocytes [20], fat oxidation [21],
energy expenditure [22] and thermogenic responses [23]
in humans. However, caffeine has not been shown to
reduce body fat in humans, so its effects upon fat metab-
olism are, in general, considered to be insignificant [24].
We have shown before that combining food ingredi-
ents involved in lipid metabolism is useful for the
prevention or treatment of obesity. For example, a
mixture of thiamine, L-arginine, caffeine, and citric acid
has been shown to have an anti-obesity effect in obese
mice and humans with a high BMI [25, 26]. We have
also shown that a combination of G-hesperidin and
caffeine reduces accumulation of body fat through (at
least in part) inhibition of hepatic lipogenesis, whereas
G-hesperidin or caffeine alone show little effect on high-
fat diet-induced obesity in mice [27].
We conducted an exploratory trial to investigate the
anti-obesity effects of a combination of G-hesperidin
and caffeine in subjects with a BMI of 24–30 kg/m2 and
serum levels of TG of 100–250 mg/dl at a potentially
effective dose of G-hesperidin (500 mg) [19] with that of
caffeine (25, 50, or 75 mg) [26].
Methods
Test samples
Composition of test samples is listed in Table 1. The
base tablet comprised lactose, cornstarch, hard starch,
and sugar ester. Lactose was substituted by G-hesperidin
and caffeine. G-hesperidin was provided from Hayashi-
bara (Okayama, Japan) and contained monoglucosyl
hesperidin (>75.0 %) and non-glycosylated hesperidin
(<25.0 %), which was confirmed by high-performance
liquid chromatography. Caffeine (purity, >98.5 %), ex-
tracted from coffee beans, was purchased from Shiratori
Pharmaceuticals (Chiba, Japan).
Subjects
A total of 160 Japanese people subjects were evaluated for
eligibility. Screening led to a study cohort of 38 men and
37 women (20–65 years) with a moderately high BMI
(24–30 kg/m2) and serum level of TG (100–250 mg/dL).
Exclusion criteria were patients who had (i) ingested
medicines and/or health-foods that might affect obesity
and serum levels of TG or (ii) consumed many bever-
ages containing caffeine (e.g. tea, green tea, coffee, and
cola). From the results of a pre-questionnaire, daily
caffeine consumption of each group was estimated as
G-hesperidin, 112 ± 104 mg/day; G-hesperidin with 25-mg
caffeine, 111 ± 76 mg/day; G-hesperidin with 50-mg caf-
feine, 89 ± 86 mg/day; G-hesperidin with 75-mg caffeine,
145 ± 104 mg/day; and placebo, 112 ± 84 mg/day.
Trial design
This trial was carried out from April to August 2013
on subjects at Fukuhara Clinic (Hokkaido, Japan) and
complied with the Declaration of Helsinki. The study
protocol was approved by the Ethics Review Board of
Miyawaki Orthopedic Clinic (Hokkaido, Japan). Proce-
dures were explained fully to subjects. Written in-
formed consent was obtained from each subject before
study commencement.
This was a randomised, double-blind placebo-controlled
trial comprising periods of pre-checking (1 week), eligibil-
ity assessment (4 weeks), intervention (12 weeks), and
post-ingestion (4 weeks).
After assessment of eligibility, 75 subjects were allocated
into five groups: 500-mg G-hesperidin; 500-mg G-hesperi-
din with 25-mg caffeine; 500-mg G-hesperidin with 50-mg
caffeine; 500-mg G-hesperidin with 75-mg caffeine; pla-
cebo (Fig. 1). Allocation was by stratified randomisation
based on age, sex, and waist circumference.
Intervention
Subjects ingested test samples as tablets (Table 1) every
day for 12 weeks. Time of ingestion of the test sample
was not dictated to patients, but was recommended to
be in the morning. Ingestion of large quantities of
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caffeine was prohibited. Ingestion of health-foods that
influence levels of TG or cholesterol, or that affect
obesity, was prohibited. Use of drugs for prolonged
periods and use of drugs that interact with caffeine was
banned. However, if a subject had been instructed to
use a drug by his/her physician, he/she reported its
name, dose, period, and indication. Dieting, drinking
excessive amounts of alcohol, and intake of medicines
known to affect lipid metabolism was prohibited.
Subjects were instructed to maintain their regular life-
style, in particular in relation to meal size and amount
of exercise.
After assessment of eligibility, subjects visited the
clinic five times at 4-week intervals. Subjects were
prohibited from eating and drinking except for water
from 9 pm the day before their visit until all checkups
had been completed.
At the day of the visit, subjects underwent a physical
examination, and analyses of blood and urine were
conducted. The diet record, walking record, and diary
were submitted at this time. At week 0 and week 12, the
abdominal fat area (AFA) was measured.
Measurement of AFA
Umbilical AFA was measured using a computed tomog-
raphy system (CT-W450; Hitachi Medical Corporation,
Tokyo, Japan) in accordance with the method described
by Tokunaga et al. [28]. Total fat area (TFA), visceral fat
area (VFA), and subcutaneous fat area (SFA) were com-
puted using Fat Scan™ v3.0 (N2 systems, Osaka, Japan).
Table 1 Composition of test samples (3 tablets/1 g)
Placebo GH GH + Caf 25 GH + Caf 50 GH + Caf 75
Energy (kcal) 4.05 4.01 4.01 4.01 4.01
Protein (g) 0 0 0 0 0
Fat (g) 0.03 0.03 0.03 0.03 0.03
Carbohydrate (g) 0.94 0.93 0.93 0.93 0.93
Glucosyl hesperidin (mg) 0 500 500 500 500
Caffeine (mg) 0 0 25 50 75
GH glucosyl hesperidin 500 mg, Caf 25, 50, 75 caffeine 25 mg, 50 mg, 75 mg
Fig. 1 Study flowchart. GH glucosyl hesperidin 500 mg, Caf 25, 50, 75 caffeine 25 mg, 50 mg, 75 mg
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Safety assessment
Haematological assessments (counts of white blood cells,
red blood cells and platelets, haemoglobin, haematocrit,
mean corpuscular volume, mean corpuscular haemoglobin,
mean corpuscular haemoglobin concentration), blood bio-
chemical assessment (total protein, albumin, total bilirubin,
aspartate aminotransferase, alanine transaminase, lactate de-
hydrogenase, alkaline phosphatase, gamma-glutamyl trans-
ferase, total cholesterol, high-density lipoprotein-cholesterol
(HDL-C), low-density lipoprotein-cholesterol (LDL-C), TG,
glucose, uric acid, urea nitrogen, creatinine, Na+, K+, Cl–,
HbA1c), and urine analyses (specific gravity, pH, protein,
sugar, urobilinogen, bilirubin, ketone bodies, occult blood
reaction) were conducted at Daiichi-Kishimoto Clinical
Laboratory (Sapporo, Japan). Anthropometric measure-
ments were undertaken at Fukuhara Clinic.
Diet and walking surveys
During the intervention period and post-ingestion
period, subjects photographed all the meals (including
snacks) that they had consumed and recorded their
contents in a diet questionnaire for 3 days before the
checkup. A nutritionist calculated values of energy,
protein, lipid, and carbohydrate using Excel Eiyokun™
v6.0 (Kenpakusha, Tokyo, Japan) from the diet question-
naires and photographs. During the same 3 days as diet
recording, the number of steps was documented (using a
pedometer) as the exercise volume.
Subject diaries
During the intervention period and post-ingestion
period, subjects recorded the time of ingestion of the
test sample and subjective symptoms in their diaries.
Statistical analyses
Values are the mean ± SD. Comparison between base-
line (week 0) and each time-point in each group was
done by the paired t-test with multiple corrections
except for AFA. After checking the equality of vari-
ance by the Bartlett method, comparisons between
groups were analysed by Dunnett’s method in the
case of equal variance, and by Steel’s method in the
case of unequal variance. Analyses were performed
using SAS v9.3 (SAS Institute, Cary, NC, USA), and
p < 0.05 was considered significant.
Results
Baseline characteristics of study participants
Seventy-five subjects completed the study. However, one
subject who completed the study with a major violation of
the test protocol owing to bereavement was excluded
from efficacy analyses. The baseline (week 0) characteris-
tics of 74 subjects are listed in Table 2. No significant dif-
ference was observed in baseline (week 0) characteristics
between groups. Safety analyses were conducted in all 75
subjects. The study flowchart is shown in Fig. 1.
Ingestion of test samples
Percentage of patients who ingested test samples in the
placebo group, 500-mg G-hesperidin group, 500-mg G-
hesperidin with 25-mg caffeine group, 500-mg G-hes-
peridin with 50-mg caffeine group, and 500-mg G-
hesperidin with 75-mg caffeine group was 99.4, 99.6,
99.8, 99.8, and 99.8 %, respectively.
Energy intake and exercise volume
Energy intake and exercise volume throughout the inter-
vention period and post-ingestion period are shown in
Table 3. Occasionally, significant differences were found
within groups, but there was no significant difference
between groups.
Effect of a combination of G-hesperidin and caffeine upon
obesity
Measurement at week 0 and week 12 as well as change
from the baseline (week 0) in AFA is shown in Table 4.
Furthermore, changes from baseline are also represented
in Fig. 2. Decreases in TFA in the G-hesperidin with 50-
mg caffeine group and in the G-hesperidin with 75-mg
caffeine group were significantly greater than those in
the placebo group. Degree of decrease of TFA appeared
to be enhanced in a caffeine dose-dependent manner.
Decreases in SFA in the G-hesperidin with 50-mg caffeine
group and G-hesperidin with 75-mg caffeine group were
significantly greater than those in the placebo group.
However, there were no significant decreases in VFA
between the placebo group and groups that ingested G-
hesperidin with or without caffeine.
Measurements during and after the intervention
period as well as changes from baseline (week 0) in body
weight, the BMI, and circumferences of the waist and
hip are shown in Table 5. Decreases in body weight at
week 8 (p = 0.045) but not at week 12 (p = 0.089) were
significantly greater in the G-hesperidin with 75-mg
caffeine group than in the placebo group. Decreases in
the BMI in the G-hesperidin with 75-mg caffeine group
were significantly greater than those in the placebo group
at week 8 and week 12. The BMI-decreasing effect of G-
hesperidin appeared to be enhanced dose-dependently by
caffeine addition. Decreases in waist circumference were
significantly greater in the G-hesperidin with 25 mg
caffeine group than in the placebo group at week-8
and at week-12. Similar decreases were observed in
the G-hesperidin with 75 mg caffeine group but were
not significant. There were no significant differences
in decreases in hip circumference between the placebo
group, and groups that ingested G-hesperidin with or
without caffeine.
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Effect of a combination of G-hesperidin and caffeine on
serum levels of lipids
Measurements during and after the intervention period
as well as changes from baseline (week 0) in serum
levels of TG, total cholesterol, HDL-C and LDL-C are
shown in Table 6. G-hesperidin has been reported to
lower the serum levels of TG in subjects with moder-
ately high levels of TG in serum [17]. However, TG
levels in the G-hesperidin-alone group did not decrease
during the intervention period, and the changes from
baseline (week 0) were not different from those of the
placebo group. TG levels in the G-hesperidin with
caffeine group also did not decrease. Occasionally,
serum levels of total cholesterol, HDL-C, and LDL-C
decreased in G-hesperidin with/without caffeine groups
during intervention periods but changes from base-
line (week 0) were not different from those in the
placebo group.
Safety assessment
Twenty-nine adverse events (AEs) were recorded during
the study. Of the seven AEs in the placebo group, three
were symptoms of a common cold, one was a pollen
allergy, one was pain, one was tinnitus, and one was
sudden deafness. Of the six AEs in the G-hesperidin
group, three were symptoms of a common cold, two
were pain, and one was conjunctivitis. Of the five AEs in
the G-hesperidin with 25 mg caffeine group, two were
symptoms of a common cold, two were digestive symp-
toms, and one was pain. Of the eight AEs in the G-
hesperidin with 50-mg caffeine group, three were digestive
symptoms, one was a symptom of a common cold, one
was pain, one was a pollen allergy, one was fatigue, and
one was irritation. Of three AEs in the G-hesperidin with
75-mg caffeine group, one was a symptom of common
cold, one was pain, and one was a pollen allergy. Of the 29
AEs, one was moderate and 28 were mild. All AEs were
Table 2 Subjects’ baseline characteristics
Placebo GH GH + Caf 25 GH + Caf 50 GH + Caf 75
Subject (Men/women) N = 14 (7/7) n = 15 (7/8) n = 15 (8/7) n = 15 (8/7) n = 15 (7/8)
Age (y) 49.4 ± 8.5 49.0 ± 10 49.1 ± 13 50.8 ± 9.8 47.3 ± 9.9
Height (cm) 163.7 ± 11 162.9 ± 9.7 162.0 ± 8.9 162.6 ± 8.4 162.6 ± 7.3
Body weight (g) 70.3 ± 9.6 70.0 ± 9.9 69.2 ± 9.0 70.5 ± 7.4 70.2 ± 6.5
BMI (kg/m2) 26.1 ± 1.1 26.2 ± 1.6 26.3 ± 1.2 26.7 ± 1.8 26.5 ± 1.2
Waist (cm) 90.9 ± 5.7 90.6 ± 3.0 90.4 ± 5.3 90.0 ± 4.7 91.0 ± 4.4
Hip (cm) 96.5 ± 5.1 96.8 ± 2.9 95.9 ± 4.4 97.1 ± 3.1 96.4 ± 4.6
Abdominal fat area
Total (cm2) 301.7 ± 50.6 304.3 ± 41.8 297.9 ± 54.8 295.1 ± 53.7 310.8 ± 43.9
Visceral (cm2) 97.2 ± 53.1 97.6 ± 27.7 107.5 ± 42.3 108.1 ± 46.1 101.1 ± 28.9
Subcutaneous (cm2) 204.6 ± 59.5 206.6 ± 45.4 190.4 ± 59.0 187.0 ± 48.0 209.8 ± 45.4
GH glucosyl hesperidin 500 mg, Caf 25, 50, 75 caffeine 25 mg, 50 mg, 75 mg, BMI Body Mass Index
Mean ± SD
Table 3 Dietary composition and exercise volume during intervention period and post- ingestion period
Intervention period Post-ingestion period
Item Group n Week-0 Week-4 Week-8 Week-12 Week-16
Energy (kcal/3d) Placebo 14 6075 ± 1336 5925 ± 934 5648 ± 1108** 5623 ± 872 5488 ± 924*
GH 15 5599 ± 1387 5748 ± 1500 5383 ± 1250 5322 ± 1259 5328 ± 1013
GH + Caf 25 15 5606 ± 1270 5512 ± 1031 5252 ± 1340 4981 ± 1291 5155 ± 1395
GH + Caf 50 15 5240 ± 1463 5774 ± 1666 5425 ± 1538 5302 ± 1723 5272 ± 1635
GH + Caf 75 15 5727 ± 929 5268 ± 1369 5546 ± 1302 5119 ± 1538 5401 ± 1618
Exercise volume (step/3d) Placebo 14 21661 ± 12162 22372 ± 9366 27058 ± 11735 25258 ± 10247 23994 ± 10039
GH 15 17118 ± 7809 22161 ± 15033 19231 ± 8677 22738 ± 11305* 20298 ± 8622
GH + Caf 25 15 19929 ± 8679 22946 ± 14412 22350 ± 16172 19656 ± 16855 22996 ± 14817
GH + Caf 50 15 23513 ± 13156 21881 ± 12157 22491 ± 9911 23005 ± 12524 24650 ± 12288
GH + Caf 75 15 18843 ± 7455 19828 ± 6532 24016 ± 8703 24036 ± 9488 23972 ± 8216
GH glucosyl hesperidin 500 mg, Caf 25, 50, 75 caffeine 25 mg, 50 mg, 75 mg
Data are the mean ± SD recorded 3 days before each check-up
*p < 0.05, **p < 0.01 vs. baseline (week-0), (paired t-test)
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judged to be unrelated to the dietary intervention, in which
the moderate AE of sudden deafness was considered to be
a result of the stress of bereavement.
Among the safety assessments undertaken, total protein
in serum at week 4 in the G-hesperidin with 25 mg caffeine
group (7.24 ± 0.23 g/dl) or at week 8 in the G-hesperidin
with 75 mg caffeine group (7.27 ± 0.39 g/dl) were signifi-
cantly greater than in the placebo group (week 4: 6.94 ±
0.19 g/dl, week 8: 7.27 ± 0.39 g/dl), and urine gravity at
week 4 in the G-hesperidin with 75 mg caffeine group
(1.013 ± 0.004 g/ml) was significantly lower than in the pla-
cebo group (1.018 ± 0.006 g/ml). However, these changes
were within the ranges of corresponding reference values.
Discussion
We conducted a randomised double-blind placebo-
controlled study to evaluate the anti-obesity effect and
serum TG-lowering effect of a combination of G-
hesperidin and caffeine in subjects with a moderately
high BMI and moderately high serum levels of TG.
Intake of G-hesperidin with 50-mg caffeine and 75-mg
caffeine showed significant decreasing effects on AFA
(especially on SFA). This fat-decreasing effect seemed to
be enhanced by the dose-dependent addition of caffeine.
Significant decreases in body weight and the BMI were
observed in the G-hesperidin with 75-mg caffeine
group compared with those in the placebo group. De-
creases in VFA in G-hesperidin with caffeine groups
were not significant compared with those in the
placebo group. Visceral adipose tissue has been pro-
posed to mediate obesity-related unfavourable levels
of insulin, glucose and lipids, but subcutaneous ab-
dominal adipose tissue has been shown to be inde-
pendent risk factor for the metabolic complications of
Table 4 Effect of G-hesperidin + caffeine tablets on abdominal fat area
Parameter Group n Week-0 Week-12 Change from baseline
Total fat area (cm2) Placebo 14 301.7 ± 50.6 318.1 ± 50.4 16.3 ± 34.1
GH 15 304.3 ± 41.8 299.7 ± 44.1 −4.6 ± 20.5
GH + Caf 25 15 297.9 ± 54.8 293.7 ± 61.5 −4.2 ± 18.2
GH + Caf 50 15 295.1 ± 53.7 286.7 ± 48.9 −8.4 ± 21.9#
GH + Caf 75 15 310.8 ± 43.9 293.9 ± 45.5 −17.0 ± 31.4##
Visceral fat area (cm2) Placebo 14 97.2 ± 53.1 102.3 ± 61.9 5.1 ± 25.9
GH 15 97.6 ± 27.7 96.6 ± 27.5 −1.1 ± 15.0
GH + Caf 25 15 107.5 ± 42.3 103.6 ± 40.0 −3.8 ± 14.5
GH + Caf 50 15 108.1 ± 46.1 109.0 ± 46.6 0.9 ± 11.3
GH + Caf 75 15 101.1 ± 28.9 96.5 ± 33.7 −4.5 ± 16.1
Subcutaneous fat area (cm2) Placebo 14 204.6 ± 59.5 215.8 ± 63.5* 11.2 ± 18.3
GH 15 206.6 ± 45.4 203.1 ± 44.2 −3.5 ± 11.8
GH + Caf 25 15 190.4 ± 59.0 190.1 ± 60.1 −0.4 ± 14.3
GH + Caf 50 15 187.0 ± 48.0 177.7 ± 44.0 −9.3 ± 17.1##
GH + Caf 75 15 209.8 ± 45.4 197.3 ± 44.4* −12.4 ± 18.7##
GH glucosyl hesperidin 500 mg, Caf 25, 50, 75 caffeine 25 mg, 50 mg, 75 mg
Mean ± SD, *p < 0.05 vs. baseline (week-0), (paired t-test), #p < 0.05, ##p < 0.01 vs. placebo
Fig. 2 Change in abdominal fat area after 12 weeks of intervention. Data are expressed as Mean ± SD. ♯:p < 0.05, ♯♯:p < 0.01 v.s. Placebo.
n = 15 in each of groups except for Placebo (n = 14). GH glucosyl hesperidin 500 mg, Caf 25, 50, 75 caffeine 25 mg, 50 mg, 75 mg
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Table 5 Anthropometric variables during the intervention period and post- ingestion periods
Intervention period post- ingestion period
Parameter Group n Week-0 Week-4 Week-8 Week-12 Week-16
Body weight (kg) Placebo 14 70.3 ± 9.6 70.1 ± 9.2 70.6 ± 9.0 70.1 ± 8.8 70.5 ± 9.3
GH 15 70.0 ± 9.9 69.5 ± 9.7 69.9 ± 9.7 69.6 ± 9.4 70.0 ± 9.7
GH + Caf 25 15 69.2 ± 9.0 69.1 ± 9.0 68.8 ± 9.2 68.6 ± 9.5 68.7 ± 9.5
GH + Caf 50 15 70.5 ± 7.4 70.2 ± 7.5 70.1 ± 7.7 69.8 ± 7.7 69.8 ± 8.0
GH + Caf 75 15 70.2 ± 6.5 69.8 ± 6.6 69.3 ± 6.9 68.8 ± 7.0 68.9 ± 7.0
ΔBody weight (kg) Placebo 14 −0.26 ± 1.1 0.24 ± 1.2 −0.19 ± 1.7 0.16 ± 1.7
GH 15 −0.44 ± 1.0 −0.09 ± 0.9 −0.39 ± 1.1 0.08 ± 1.4
GH + Caf 25 15 −0.11 ± 0.8 −0.39 ± 1.0 −0.57 ± 1.1 −0.48 ± 1.7
GH + Caf 50 15 −0.29 ± 1.1 −0.44 ± 1.3 −0.67 ± 1.4 −0.67 ± 1.8
GH + Caf 75 15 −0.36 ± 1.0 −0.88 ± 1.4# −1.43 ± 2.0 −1.27 ± 2.2
BMI (kg/m2) Placebo 14 26.1 ± 1.1 26.1 ± 1.2 26.3 ± 1.1 26.1 ± 1.3 26.2 ± 1.2
GH 15 26.2 ± 1.6 26.1 ± 1.6 26.2 ± 1.6 26.1 ± 1.6 26.3 ± 1.6
GH + Caf 25 15 26.3 ± 1.2 26.2 ± 1.3 26.1 ± 1.3 26.0 ± 1.4 26.1 ± 1.6
GH + Caf 50 15 26.7 ± 1.8 26.6 ± 1.8 26.5 ± 1.9 26.4 ± 1.9 26.4 ± 2.0
GH + Caf 75 15 26.5 ± 1.2 26.4 ± 1.3 26.2 ± 1.3 25.9 ± 1.3* 26.0 ± 1.3
ΔBMI (kg/m2) Placebo 14 −0.07 ± 0.37 0.14 ± 0.39 −0.02 ± 0.58 0.08 ± 0.57
GH 15 −0.15 ± 0.36 −0.01 ± 0.38 −0.13 ± 0.42 0.03 ± 0.53
GH + Caf 25 15 −0.05 ± 0.31 −0.14 ± 0.40 −0.23 ± 0.40 −0.19 ± 0.65
GH + Caf 50 15 −0.13 ± 0.42 −0.19 ± 0.52 −0.28 ± 0.56 −0.27 ± 0.70
GH + Caf 75 15 −0.13 ± 0.41 −0.35 ± 0.55# −0.56 ± 0.74# −0.51 ± 0.84
Waist (cm) Placebo 14 90.9 ± 5.7 90.7 ± 5.5 91.1 ± 5.1 91.3 ± 4.8 91.3 ± 5.3
GH 15 90.6 ± 3.0 90.6 ± 3.5 90.6 ± 3.4 90.6 ± 3.3 90.6 ± 3.8
GH + Caf 25 15 90.4 ± 5.3 89.9 ± 5.9 89.3 ± 6.0* 89.1 ± 6.2* 89.5 ± 6.4
GH + Caf 50 15 90.0 ± 4.7 89.6 ± 5.0 89.7 ± 5.2 89.1 ± 5.8 88.8 ± 6.5
GH + Caf 75 15 91.0 ± 4.4 91.0 ± 3.9 90.3 ± 4.0 89.9 ± 3.5 89.8 ± 3.1
ΔWaist (cm) Placebo 14 −0.12 ± 0.9 0.19 ± 1.4 0.44 ± 2 0.42 ± 2.1
GH 15 0.01 ± 1.0 −0.01 ± 1.4 −0.02 ± 1.3 −0.03 ± 1.3
GH + Caf 25 15 −0.49 ± 1.1 −1.17 ± 1.4# −1.31 ± 1.6# −0.96 ± 2.2
GH + Caf 50 15 −0.31 ± 1.1 −0.28 ± 1.3 −0.82 ± 1.9 −1.12 ± 2.6
GH + Caf 75 15 0.05 ± 1.0 −0.66 ± 0.9 −1.11 ± 1.7 −1.21 ± 2.2
Hip (cm) Placebo 14 96.5 ± 5.1 96.3 ± 5.3 96.5 ± 5.1 96.9 ± 5.5 97.1 ± 5.6
GH 15 96.8 ± 2.9 96.6 ± 2.8 96.9 ± 2.8 96.4 ± 3.1 96.6 ± 2.8
GH + Caf 25 15 95.9 ± 4.4 96.1 ± 4.0 96.1 ± 4.0 96.0 ± 4.5 96.0 ± 5.0
GH + Caf 50 15 97.1 ± 3.1 96.8 ± 3.2 97.0 ± 3.2 97.0 ± 3.5 97.0 ± 3.4
GH + Caf 75 15 96.4 ± 4.6 96.2 ± 4.6 96.0 ± 4.6 95.5 ± 4.5 95.6 ± 4.6
ΔHip (cm) Placebo 14 −0.17 ± 0.7 0.01 ± 1.1 0.37 ± 1.6 0.64 ± 1.4
GH 15 −0.17 ± 0.8 0.05 ± 1.3 −0.41 ± 1.2 −0.23 ± 1.5
GH + Caf 25 15 0.23 ± 0.8 0.17 ± 1.0 0.13 ± 1.4 0.06 ± 2.0
GH + Caf 50 15 −0.26 ± 0.8 −0.11 ± 1.3 −0.08 ± 1.7 −0.13 ± 2.0
GH + Caf 75 15 −0.21 ± 1.0 −0.39 ± 1.2 −0.85 ± 1.8 −0.79 ± 2.0
GH glucosyl hesperidin 500 mg, Caf 25, 50, 75 caffeine 25 mg, 50 mg, 75 mg, BMI Body Mass Index
Mean ± SD, *p < 0.05, vs. baseline (week-0), (paired t-test), #p < 0.05 vs. placebo (Dunnett’s test or Steel’s test)
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Table 6 Blood biochemical parameters during the intervention period and post- ingestion period
Intervention period post- ingestion period
Parameter Standard value Group n Week-0 Week-4 Week-8 Week-12 Week-16
Triglyceride (mg/dl) 50 ~ 149 Placebo 14 144 ± 65 142 ± 43 131 ± 55 141 ± 61 119 ± 44
GH 15 128 ± 55 132 ± 49 134 ± 71 153 ± 70 152 ± 58
GH + Caf 25 15 126 ± 48 137 ± 53 135 ± 47 129 ± 36 127 ± 47
GH + Caf 50 15 133 ± 70 137 ± 29 136 ± 50 148 ± 66 144 ± 54
GH + Caf 75 15 156 ± 74 136 ± 35 127 ± 40 134 ± 39 135 ± 41
ΔTriglyceride (mg/dl) Placebo 14 −1.4 ± 58 −12.4 ± 49 −2.6 ± 57 −24.9 ± 50
GH 15 4.3 ± 33 5.5 ± 46 24.6 ± 60 24.0 ± 47
GH + Caf 25 15 11.1 ± 49 8.9 ± 51 3.0 ± 44 1.0 ± 46
GH + Caf 50 15 4.4 ± 69 2.9 ± 70 15.3 ± 45 10.7 ± 54
GH + Caf 75 15 −21.9 ± 80 −29.3 ± 66 −22.7 ± 61 −21.3 ± 74
Total cholesterol (mg/dl) 150 ~ 219 Placebo 14 220 ± 37 216 ± 44 215 ± 39 220 ± 39 219 ± 45
GH 15 229 ± 29 217 ± 29* 224 ± 29 224 ± 30 222 ± 28
GH + Caf 25 15 213 ± 27 210 ± 24 202 ± 30 205 ± 26 205 ± 31
GH + Caf 50 15 222 ± 34 218 ± 37 216 ± 34 222 ± 34 219 ± 40
GH + Caf 75 15 241 ± 27 228 ± 31 225 ± 27* 227 ± 24* 233 ± 23
ΔTotal cholesterol (mg/dl) Placebo 14 −4.8 ± 20 −5.2 ± 16 −0.1 ± 18 −1.9 ± 24
GH 15 −12.5 ± 17 −5.3 ± 15 −5.8 ± 14 −7.6 ± 16
GH + Caf 25 15 −3.3 ± 17 −11.3 ± 21 −8.2 ± 16 −8.5 ± 17
GH + Caf 50 15 −4.5 ± 16 −6.1 ± 18 0 ± 15 −3.2 ± 22
GH + Caf 75 15 −5.3 ± 22 −15.5 ± 21 −13.1 ± 14 −7.6 ± 22
HDL-cholesterol (mg/dl) Men: Placebo 14 54.6 ± 12 51.8 ± 10 51.5 ± 12 51.8 ± 11 53.0 ± 12
40 ~ 80 GH 15 53.9 ± 10 51.8 ± 10 52.3 ± 9 50.9 ± 9 51.7 ± 9
Women: GH + Caf 25 15 53.9 ± 11 53.4 ± 13 49.3 ± 10** 49.9 ± 11** 50.9 ± 10
40 ~ 90 GH + Caf 50 15 53.6 ± 11 51.5 ± 9 49.7 ± 6 50.1 ± 8 51.7 ± 8
GH + Caf 75 15 56.5 ± 11 55.9 ± 12 55.0 ± 12 54.3 ± 11 55.1 ± 10
ΔHDL-cholesterol (mg/dl) Placebo 14 −2.8 ± 6.2 −3.1 ± 4.7 −2.8 ± 5.0 −1.6 ± 5.6
GH 15 −2.1 ± 5.4 −1.6 ± 4.4 −3.0 ± 5.6 −2.1 ± 4.8
GH + Caf 25 15 −0.5 ± 4.9 −4.6 ± 4.4 −4.0 ± 3.9 −3.1 ± 4.4
GH + Caf 50 15 −2.1 ± 5.1 −3.9 ± 7.1 −3.5 ± 4.8 −1.9 ± 8.2
GH + Caf 75 15 −0.3 ± 6.7 −1.5 ± 6.4 −2.2 ± 5.7 −1.4 ± 5.8
LDL-cholesterol (mg/dl) 70 ~ 139 Placebo 14 147 ± 41 142 ± 44 145 ± 40 144 ± 39 148 ± 47
GH 15 151 ± 29 140 ± 24 148 ± 30 140 ± 30* 144 ± 25
GH + Caf 25 15 140 ± 30 137 ± 20 134 ± 27 133 ± 25 134 ± 27
GH + Caf 50 15 149 ± 37 147 ± 40 147 ± 36 148 ± 36 147 ± 37
GH + Caf 75 15 161 ± 28 155 ± 29 152 ± 19 149 ± 21 160 ± 24
ΔLDL-cholesterol (mg/dL) Placebo 14 −5.6 ± 17 −2.4 ± 15 −2.8 ± 16 0.9 ± 21
GH 15 −11.0 ± 17 −3.1 ± 15 −10.6 ± 14 −7.5 ± 14
GH + Caf 25 15 −2.6 ± 21 −5.9 ± 18 −7.5 ± 14 −5.9 ± 15
GH + Caf 50 15 −2.7 ± 16 −2.3 ± 18 −1.0 ± 14 −2.8 ± 15
GH + Caf 75 15 1.1 ± 31 −8.9 ± 20 −12.2 ± 21 −1.5 ± 23
GH glucosyl hesperidin 500 mg, Caf 25, 50, 75, caffeine 25 mg, 50 mg, 75 mg, BMI Body Mass Index, LDL low-density lipoprotein, HDL high-density lipoprotein
Mean ± SD *p < 0.05, **P < 0.01 vs. baseline (week 0) (paired t-test)
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obesity [29–31]. Therefore, our observations that a
combination of G-hesperidin and caffeine decreased
AFA may have clinical significance.
We have developed anti-obesity agents containing
dietary components that affect lipid metabolism. Their
effectiveness has been evaluated in non-insulin-
dependent diabetic KK mice induced to develop obesity
by feeding with a high-fat diet. Among the agents exam-
ined in this model, a mixture of thiamine, arginine, caf-
feine, and citric acid, as well as a mixture of arginine,
caffeine, soy isoflavones and carnitine, have shown
prominent anti-obesity effects [25, 32]. Recently, we have
shown that a combination of G-hesperidin and caffeine
decreased weights of subcutaneous fat and visceral fat
effectively in high-fat diet-induced obese mice [27]. We
consider the mechanism of its anti-obesity effect is par-
tially through the inhibition of hepatic lipogenesis (Fig. 3)
[27]. In addition to the effectiveness of a mixture of
thiamine, arginine, caffeine and citric acid in the treat-
ment of obesity in humans [26], we showed an anti-
obesity effect of a combination of G-hesperidin and caf-
feine in moderately obese subjects in the present study.
Therefore, the effectiveness of anti-obesity agents com-
prising dietary components observed in obese KK mice
can be expected to have a similar effect in humans.
Reports have shown that 12-week intake of G-hesperidin
(500 mg) lowers serum levels of TG in subjects with
moderately high levels of TG in serum [17]. In con-
trast to those observations, intake of G-hesperidin
with or without caffeine had no effect on serum levels
of TG in subjects with moderately high levels of TG.
Unlike previous studies, we recruited subjects with a
moderately high BMI in addition to a moderately high
level of TG. It has been reported that plasma levels
of TG in obese subjects do not decrease efficiently in
response to insulin, are overproduced, or are resistant
to clearance [33]. Such changes in TG metabolism in
obese subjects may affect the action of G-hesperidin,
leading to the slight effect of G-hesperidin on serum
levels of TG in obese subjects.
In the present study, mean daily consumption of caf-
feine other than during intervention was about 100 mg in
subjects of each group. Nevertheless, a dose–response of
caffeine from 25 mg to 75 mg was observed in the anti-
obesity effects of this combination. Hence, concomitant
(but not habitual) intake of caffeine with G-hesperidin
might be important for the anti-obesity activity of this
combination. Indeed, in studies demonstrating the anti-
obesity effect of caffeine-containing components, caffeine
was taken concomitantly with other ingredients [34, 35]. If
Fig. 3 Fat-reducing effect of the combination of G-hesperidin and caffeine is partially through the inhibition of hepatic lipogenesis. G6P,
Glucose-6-phosphate; G6PD, Glucose-6-phosphate dehydrogenase; ACC, Acetyl-CoA carboxylase; FAS, Fatty acid synthase; VLDL, very low
density lipoprotein
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concomitant intake is important, then whether single
intake of such a low dose of caffeine has physiological
relevance is of particular importance. It has been reported
that a single dose of 12.5 mg caffeine affects cognitive
performance [36] and that 32-mg caffeine improves audi-
tory vigilance and visual reaction time [37]. Therefore,
concomitant intake of caffeine may have physiological
activity and synergize with G-hesperidin. Further investi-
gations are required to clarify the importance of concomi-
tant intake of caffeine and G-hesperidin.
Conclusions
Our results showed that intake of a combination of
500-mg G-hesperidin and 75-mg caffeine for 12 weeks
significantly reduced abdominal fat (especially subcutane-
ous fat), body weight and the BMI in subjects with a
moderately high BMI. Therefore, a combination of G-
hesperidin and caffeine may be useful for the prevention
or treatment of obesity.
Abbreviations
AFA: abdominal fat area; BMI: body mass index; G-hesperidin: glucosyl
hesperidin; TG: triglyceride.
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